Thrombosis research · 2025
Cost of immune tolerance induction according to its outcome in people with hemophilia A and inhibitors: results from the Co$tIT study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Franco Vivian Karla Brognoli, Camelo Ricardo Mesquita, Dias Maíse Moreira, Oliveira Andrea Gonçalves de, Santos Andrea Vilela de Oliveira, Lorenzato Cláudia Santos, Stephanes Camila, Ribeiro Rosângela de Albuquerque, Beserra Nathália Martins, Teodoro Juliana Alvares, Rezende Suely Meireles
Аннотация
BACKGROUND: Immune Tolerance Induction (ITI) is indicated for people with hemophilia A (PwHA) with inhibitors. It is not known whether the costs differ among ITI outcomes.
AIM: To assess the costs of clotting factor concentrates (CFC) according to ITI outcomes.
METHODS: This retrospective cohort study included 91 PwHA who completed a first course of ITI. We evaluated the costs with CFC 12 months before (pre-ITI), during and 12 months after ITI (post-ITI), according to ITI outcome. We compared costs in each period, between pre- and post-ITI, and evaluated the determinants of costs during ITI.
RESULTS: A total of 32 %, 38 % and 30 % of PwHA achieved complete (CS), partial success (PS), and failed ITI, respectively. The mean cost per PwHA during ITI was US$1.18 million; US$355,838 in CS, US$724,986 in PS, and US$2,653,217 in the failure group. During ITI, approximately 65 % of the variability of the mean cost/kg was explained by the outcome of ITI (failure or PS), duration of ITI, use of prophylactic bypassing agents, and use of incremental FVIII regimen. In post-ITI, we observed about 50 % and 22 % reduction of mean cost/kg in CS and PS, respectively, while failing ITI resulted in increased costs of over 100 % compared with pre-ITI. Regardless of the outcome, in post-ITI, the annualized bleeding rate reduced when compared with pre-ITI.
CONCLUSIONS: Costs with CFC during ITI were the lowest with CS, followed by PS and failure. In comparison with pre-ITI, successful ITI was associated with reduced costs, already noticed in the first year post-ITI.
AIM: To assess the costs of clotting factor concentrates (CFC) according to ITI outcomes.
METHODS: This retrospective cohort study included 91 PwHA who completed a first course of ITI. We evaluated the costs with CFC 12 months before (pre-ITI), during and 12 months after ITI (post-ITI), according to ITI outcome. We compared costs in each period, between pre- and post-ITI, and evaluated the determinants of costs during ITI.
RESULTS: A total of 32 %, 38 % and 30 % of PwHA achieved complete (CS), partial success (PS), and failed ITI, respectively. The mean cost per PwHA during ITI was US$1.18 million; US$355,838 in CS, US$724,986 in PS, and US$2,653,217 in the failure group. During ITI, approximately 65 % of the variability of the mean cost/kg was explained by the outcome of ITI (failure or PS), duration of ITI, use of prophylactic bypassing agents, and use of incremental FVIII regimen. In post-ITI, we observed about 50 % and 22 % reduction of mean cost/kg in CS and PS, respectively, while failing ITI resulted in increased costs of over 100 % compared with pre-ITI. Regardless of the outcome, in post-ITI, the annualized bleeding rate reduced when compared with pre-ITI.
CONCLUSIONS: Costs with CFC during ITI were the lowest with CS, followed by PS and failure. In comparison with pre-ITI, successful ITI was associated with reduced costs, already noticed in the first year post-ITI.